Need more information about GEArray products? please visit Microarray Home or send Email to Technical Support

Genes Directly Associated with breast Cancer
AZGP1, CDKN1A, CLDN7, CLU, DST, ERBB2, FGF1, FLRT1, GABRP, GNAS, ID2, ITGA6, ITGB4, KLF5, KRT19, KRT86 (KRTHB6), LCN2, MARCKSL1, MT3, MUC1, PTGS2, RAC2, S100A2, SCGB1D2, SCGB2A1, SCGB2A2, SPRR1B, THBS1, THBS2, THBS4, TNFAIP2, TOB2.

Genes Associated with the Estrogen Receptor Signaling Pathway
Estrogen Receptors: ESR1, ESR2.
Estrogen Receptor Binding: DDX54, NCOA6, NRIP1, NSD1, PHB2, PPARGC1B, RERG.
Other Genes Associated with the Estrogen Receptor Signaling Pathway: AR, ARID1A, BMPR1B, C3, CCND1, CD47, CTSD, EGLN2, GATA3, HSD17B1, HSPB1, KRT18, KRT19, PGR, SERPINA3, SLC7A5, STC2, SULT1E1, TFF1, TFF3.

Genes Associated with Breast Cancer Prognosis
BAD, BAG1, BCL2, CCNA1, CCNA2, CCND1, CCNE1, CCNE2, CDH1, CDKN1B, CDKN2A, COL6A1, CTNNB1, CTSB, EGFR, ERBB2, ESR1, ESR2, F3, FAS, FASLG, FOSL1, GATA3, GSN, IGFBP2, IGFBP5, IL2RA, IL6, IL6R, IL6ST, ITGA6, JUN, KLK5, KRT19, MAP2K7, MKI67, NGFB, NGFR, NME1, PGR, PLAU, PTEN, SERPINB5, SERPINE1, TGFA, THBS1, TIE1, TOB2, TOP2A, TP53, VEGF, VIM.

Genes Associated with Response to Chemotherapy
BCL2, BCL2L2, CD44, COX17, CTSD, CYP19A1, DLC1, ESR1, ESR2, HMGB1, KIT, NFYB, PAPPA, PGR, PPP1R15A, RPL27, VEGF.

GEArray microarrays are shipped at ambient temperature enclosed in either a HybTube or ExpressPak Storage Box. They should be stored at -20 ºC upon receipt.

1. Jiang Y, et al. Discovery of differentially expressed genes in human breast cancer using subtracted cDNA libraries and cDNA microarrays. Oncogene 2002 Mar 28; 21 (14): 2270-82
2. Sotiriou C, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002; 4 (3): R3.
3. Ahr A, et al. Molecular classification of breast cancer patients by gene expression profiling. J Pathol. 2001 Oct; 195 (3): 312-20.
4. Gruvberger S. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 2001 Aug 15; 61 (16): 5979-84.
5. Zajchowski DA, et al. Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res. 2001 Jul 1; 61 (13): 5168-78
6. Kim H, et al. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer. 2001 Mar 2; 84 (5): 643-50.
7. Umekita Y, et al. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer. 2000 Nov 20; 89 (6): 484-7.
8. Hui R, et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res. 2000 Jul; 6 (7): 2777-87.
9. Nelson NJ. Plasminogen activator proteins tested as prognostic markers. J Natl Cancer Inst. 2000 Jun 7; 92 (11): 866-8.
10. Karczewska A, et al. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer 2000 May 1; 88 (9): 2061-71.
11. Lin SY, et al. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci U S A. 2000 Apr 11; 97 (INK4a gene expression and methylation in primary breast 8): 4262-6.
12. Martin KJ, et al. Linking gene expression patterns to therapeutic groups in breast cancer. Cancer Res. 2000 Apr 15; 60 (8): 2232-8.
13. Nacht M, et al. Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res. 1999 Nov 1; 59 (21): 5464-70.